NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Setting aside Toucan VC, When hearing about this series C, I can’t help but remember LP was a VC prior to all this. She knows the ins, outs and progression of series A to series B to Series C.

I can’t help but think how Ex’s first reaction on this series c was to recall NWBO’s recent 10q SOW 6 seemed to infer far more progress with Flaskworks then perhaps even Shashi Murthy let on at ASCO.

This would require massive expansion, but just as importantly, would need to develop the expansion rapidly in such a way to morph a pre-revenue company into a revenue positive company.

Scotty of course is right, that this will ultimately cause some dilution, but normally series C, unlike series a and b investors, are looking for returns in short order from revenue generation and PPS increase. That’s why series C are often composed of new players as well as old players. The new players have the muscle/juice/capital to make this a functioning biotech, and in my mind, will need to also buy on the market sooner than later.